Welcome to our dedicated page for Radius Health news (Ticker: RDUS), a resource for investors and traders seeking the latest updates and insights on Radius Health stock.
Radius Recycling, Inc. (formerly Schnitzer Steel Industries, Inc.) has been a frequent subject of corporate, financial, and transaction-related news due to its role in metals recycling and steel manufacturing and its transition from a public company to a wholly owned subsidiary of Toyota Tsusho America, Inc. News coverage for the former Nasdaq-listed symbol RDUS includes quarterly and annual financial results, operating updates, and major corporate events.
Company earnings releases have provided details on ferrous and nonferrous sales volumes, finished steel volumes, average net selling prices, rolling mill utilization, and adjusted EBITDA. These reports explain how changes in global ferrous and finished steel prices, nonferrous demand, scrap availability, and productivity initiatives have affected margins and profitability. They also highlight the company’s cost reduction and productivity programs, investments in advanced metal recovery technologies, and expansion of its recycling services platform.
News items have also covered governance and leadership developments, such as the appointment of a chief operating officer and new board members, reflecting ongoing attention to operational performance and strategic direction. In addition, Radius has regularly announced quarterly cash dividends, noting a long history of paying dividends since its initial public offering.
A major focus of recent news has been the definitive merger agreement under which Toyota Tsusho America, Inc. agreed to acquire Radius Recycling, Inc. Press releases and subsequent SEC filings describe the agreed cash consideration for Radius shareholders, the rationale for combining the businesses, and the expectation that Radius would continue to operate from its Portland, Oregon headquarters with its brands and facilities retained. Later news documented the receipt of required regulatory approvals, shareholder approval, and the closing of the merger.
Following completion of the transaction and the delisting and deregistration of RDUS, this news page functions as an archive of historical announcements, financial updates, and corporate actions related to Radius Recycling, Inc. during its period as a publicly traded company.
Radius Health reported a 17% increase in new TYMLOS® patients in January 2021, totaling 1,692 new patients compared to prior months. The company highlighted recent publications in the Journal of Bone & Mineral Research and Journal of Clinical Endocrinology & Metabolism that underscore the efficacy and safety of the abaloparatide molecule. Ongoing regulatory activities are on schedule in the U.S., Japan, Canada, and the E.U. Radius is also focused on completing the ATOM study and wearABLe study for further development of TYMLOS.
On January 6, 2021, Radius Health, Inc. (Nasdaq: RDUS) announced that CEO Kelly Martin will present a virtual corporate update at the 39th Annual J.P. Morgan Healthcare Conference on January 13 at 9:10 a.m. EST. A live webcast can be accessed through the Investors section of Radius' website, with a replay available for 90 days post-presentation.
Radius is a biopharmaceutical company focused on endocrine therapeutics, with its lead product TYMLOS approved for treating high-risk osteoporosis in postmenopausal women. The company is also exploring treatments for men with osteoporosis and hormone-receptor positive breast cancer.
Radius Health has acquired global development rights to RAD011, a synthetic cannabidiol oral solution, for $12.5 million, with up to $60 million in milestone payments. The drug targets Prader-Willi syndrome (PWS), an orphan disease, and has received Orphan Drug and Fast Track Designation from the FDA. The acquisition will be funded through existing operations, minimizing shareholder dilution. Radius expects to initiate a pivotal Phase 2/3 study for PWS in late 2021, with potential top-line data available by 2023. A one-time charge of up to $16 million is expected in Q4 2020 due to the acquisition.
On January 5, 2021, Endo International plc (NASDAQ: ENDP) announced a licensing agreement with Radius Health, Inc. (NASDAQ: RDUS) for the exclusive commercialization of abaloparatide in Canada, through its subsidiary Paladin Labs Inc. Abaloparatide is an investigational treatment for osteoporosis, with Paladin expected to file a New Drug Submission with Health Canada by Q1 2022. The drug is not yet approved in Canada, but Endo aims to address a significant treatment gap for osteoporosis patients.
Radius Health has formed an agreement with Endo Ventures to commercialize and distribute abaloparatide in Canada. This partnership includes an upfront payment and milestone payments totaling around $8 million, plus tiered royalties on net sales. Paladin Labs will manage all commercial activities, targeting a New Drug Submission to Health Canada for TYMLOS® by early 2022. The initiative marks a strategic effort to expand abaloparatide's presence in select ex-U.S. markets, reflecting Radius's commitment to growth in 2021.
Radius Health, Inc. (Nasdaq: RDUS) has appointed Machelle Sanders and Dr. Andrew C. von Eschenbach to its board of directors, filling vacancies left by Jessica Hopfield, Ph.D. and Tony Rosenberg. Sanders brings over 25 years of pharmaceutical experience, having previously led Biogen's operations for its MS franchise. Dr. von Eschenbach, a former FDA commissioner, adds significant expertise in translating science into therapeutics. Chairman Owen Hughes expressed confidence in their contributions to Radius's emerging pipeline as the company refines its focus.
Radius Health, Inc. (Nasdaq: RDUS) reported continued growth in net new patients for TYMLOS-SC, with 1,326 new patients added in November 2020, marking an 8.0% increase from the previous average. The company is on track for a record quarter in TYMLOS-SC net revenue, surpassing the previous high of $56.7 million from Q4 2019. Additionally, Radius formed a research agreement with Massachusetts General Hospital to explore small molecules for musculoskeletal diseases. Peter Butler, MD, has been appointed as Head of Clinical Development for the abaloparatide program.
Radius Health (RDUS) reported Q3 2020 net sales of TYMLOS at $50.4 million, marking an 8% year-over-year increase. The total revenue for the quarter reached $77.8 million, supported by a significant rise in net new U.S. patients, increasing by 10% in October. The company maintains a cash balance of $126 million, ensuring operational funding for at least a year. However, Radius faced a net loss of $6.3 million for the quarter, though an improvement compared to last year's loss of $30 million. Japan's market launch of abaloparatide injection is on track for 2021.
Radius Health, Inc. (RDUS) announced significant clinical and business developments. Key highlights include the completion of enrollment in three pivotal Phase III clinical trials for osteoporosis treatments and a successful data presentation at the ASBMR meeting. The company also completed two business transactions, focusing on its oncology assets and repositioning its commercial strategy towards high-risk fracture patients. Additionally, operational improvements resulted in reduced sales territories and increased operational efficiency.
Radius Health (Nasdaq: RDUS) announced the release of its third quarter financial results on November 5, 2020, with a conference call scheduled at 8:30 a.m. ET. Investors can access the call via domestic and international dial-in numbers, with a replay available later the same day. Radius focuses on developing innovative endocrine therapeutics, including its FDA-approved product, TYMLOS, for postmenopausal women with osteoporosis. The company's pipeline includes investigational treatments for osteoporosis in men and hormone-receptor positive breast cancer.